Jeremy Pantin

Jeremy Pantin

Auto-generated profile, based on publicly available information

Jeremy Pantin

Georgia Regents University Cancer Center, Augusta, GA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2009 in Transfusion
Verified
Journal Article
Closed access
PDF file
JDJennifer Daniel‐Johnson
Jennifer Daniel‐Johnson
SLSusan Leitman
Susan Leitman
HKHarvey Klein
Harvey Klein
HAHarvey Alter
Harvey Alter
ALAgnes Lee‐Stroka
Agnes Lee‐Stroka
KQKaren Quillen
Karen Quillen

24 July 2017 in British Journal of Haematology
Verified
Journal Article
Closed access
BABenjamin Andrick
Benjamin Andrick
AAAbdulrahman Alwhaibi
Abdulrahman Alwhaibi
DDDavid L. DeRemer
David L. DeRemer
SQSameera Quershi
Sameera Quershi
RKRahil Khan
Rahil Khan
JPJeremy Pantin
Jeremy Pantin

5 February 2015 in American Journal of Transplantation
Verified
Journal Article
Open access
JPJ.M. Pantin
J.M. Pantin
RHR.F. Hoyt
R.F. Hoyt
OAO. Aras
O. Aras
NSN. Sato
N. Sato
MCM.Y. Chen
M.Y. Chen
RCR.W. Childs
R.W. Childs
Intrabone (IB) hematopoietic cell transplantation (HCT) of umbilical cord blood in humans remains experimental and the technique has not been optimized. It is unknown whether hematopoietic progenitor cells (HPCs) injected IB are initially retained in the marrow or rapidly enter into the venous circulation before homing to the marrow. To develop an IB-injection technique that maximizes HPC marrow-retention, we tracked radiolabeled human HPCs following IB-injection into swine. We developed a method to radionuclide-label HPCs using a long-lived positron emitter (89) Zr and protamine sulfate that resulted in cellular-retention of low-dose radioactivity. This approach achieved radioactivity levels sufficient for detection by positron emission tomography with both high sensitivity and spatial resolution when fused with computed tomography. We found that conditions utilized in pilot IB-HCT clinical trials conducted by others led to both rapid drainage into the central venous circulation and cellular extravasation into surrounding muscle and soft tissues. By optimizing the needle design, using continuous real-time intra-marrow pressure monitoring, and by reducing the infusion-volume and infusion-rate, we overcame this limitation and achieved high retention of HPCs in the marrow. This method of IB cellular delivery is readily applicable in the clinic and could be utilized in future investigational IB-HCT trials aimed at maximizing marrow retention of HPCs.

1 September 2014 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
JPJeremy Pantin
Jeremy Pantin
XTXin Tian
Xin Tian
NGNancy Geller
Nancy Geller
CRCatalina Ramos
Catalina Ramos
LCLisa Cook
Lisa Cook
RCRichard W. Childs
Richard W. Childs
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by intravascular hemolysis, venous thrombosis, and bone marrow failure. Seventeen patients with debilitating PNH, including 8 who were HLA-alloimmunized, underwent a reduced-intensity allogeneic hematopoietic cell transplantation (HCT). All received cyclophosphamide/fludarabine +/- antithymocyte globulin followed by a granulocyte colony-stimulating factor-mobilized HCT from an HLA-matched relative. Glycosylphosphatidylinositol-negative neutrophils were detectable after engraftment but disappeared completely at a median 100 days after transplantation. With a median follow-up of nearly 6 years, 15 patients (87.8%) survived, all without any evidence of PNH, transfusion independent, and off anticoagulation. Allogeneic reduced-intensity HCT remains a curative therapeutic option for PNH patients who are not candidates for eculizumab treatment.

26 June 2015 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
PVP. T. Vo
P. T. Vo
JPJ. Pantin
J. Pantin
CRC. Ramos
C. Ramos
LCL. Cook
L. Cook
ECE. Cho
E. Cho
RCR. W. Childs
R. W. Childs
Severe aplastic anemia (SAA) is a rare disorder leading to bone marrow failure, which if left untreated, is invariably fatal. Conventional therapies with immunosuppressive therapy or allogeneic hematopoietic stem cell transplantation (HSCT) are highly effective. HSCT can offer a greater outcome in younger patients who have an available HLA match-related donor. Recent studies showing the addition of antithymocyte globulin (ATG) to the conditioning regimen improves engraftment and reduces the risk of graft-versus-host disease (GVHD).There are currently two ATG preparations in the USA, equine (or horse) and rabbit ATG. These agents are pharmacologically distinct, having significant differences in their pharmacokinetics and in vivo immunosuppressive effects [N Engl J Med 365(5):430–438, 2011]. Here, we report a case of two monozygotic twins with constitutional SAA that evolved to myelodysplastic syndrome (MDS) who both underwent allogeneic peripheral blood stem cell transplantation (PBSC) from the same single HLA antigen mismatched sibling donor with the only difference in the transplant regimen being the type of ATG used in the preparative regimen; one twin received horse ATG and the other received rabbit ATG during conditioning. This report emphasizes that dramatic differences in donor T cell chimerism and clinical outcomes including GVHD can occur as a consequence of the type of ATG that is utilized in the transplant conditioning regimen. These differences highlight that these agents should not be considered interchangeable drugs when used in this setting.